Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 clinical trial of SYL1001

Trial Profile

A phase 3 clinical trial of SYL1001

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Tivanisiran (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 06 Jun 2017 New trial record
    • 01 Jun 2017 According to a PharmaMar media release, this study is designed to support the submission of a New Drug Application (NDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top